Further Development of XenoPort (XNPT) '829 is Unwarranted, Cowen Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
RBC Capital Defends XenoPort (XNPT); Analyst Notes M&A Potential
September 15, 2015 1:30 PM EDTRBC Capital analyst Michael J. Yee defended XenoPort (NASDAQ: XNPT) amid weakness following the release of '829 data, saying shares are close to a floor, while noting potential M&A.
"Psoriasis data shows clear efficacy as we expected but undifferentiated GI side effects vs other fumarates and CELG Otezla. But if the market cap is $315M now and there is at least theoretical $200-300M + of takeout value on Horizant ($4-5/share), then Horizant could be cheap or '829 is... More
XenoPort's (XNPT) XP-829 Efficacy 'Looks Good' - RBC Capital
September 15, 2015 8:03 AM EDTRBC Capital maintained an Outperform rating on XenoPort (NASDAQ: XNPT) with a price target of $10. Earlier XenoPort announced positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis. Analyst Michael J. Yee... More
XenoPort (XNPT) Announces Significant Prelim. Top-Line Data from XP23829 Phase 2 in Psoriasis
September 15, 2015 6:34 AM EDTXenoPort (NASDAQ: XNPT) announced positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis. XP23829 met its primary endpoint in both 800 mg once daily and 400 mg twice daily doses, demonstrating statistically significant improvements in percent change from baseline to week 12 in Psoriasis Area and Severity Index (PASI) score. XP23829 is a patented prodrug of monomethyl fumarate (MMF) in a novel oral formulation that was designed to potentially offer physicians and patients an effective, better tolerated and easier to use therapeutic option to currently... More
